PORTLAND, OR, Feb. 06, 2023 (GLOBE NEWSWIRE) — Based on data from Allied Market Research, the global HPV Testing and Pap Testing Market generated US$3.7 billion in 2021 and is expected to reach US$6.7 billion by 2031, at a CAGR of 6.1% from 2022 to 2031. Human papillomavirus (HPV) testing and Pap tests are two important early detection tests for cervical cancer. The HPV test is a separate test that checks for the presence of the HPV virus, which is one of the main causes of cervical cancer. The HPV test can be performed at the same time as a Pap test or as a separate test. The frequency of HPV testing depends on factors such as age, previous test results, and other health factors. A Pap test, also known as a Pap smear, is a procedure in which a healthcare provider takes cells from the cervix to look for changes that could lead to cervical cancer. This test is usually done every 3 years in women ages 21 to 65.

Download free sample report: https://www.alliedmarketresearch.com/request-sample/14742

The report provides a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscapes, and competitive scenarios. The report is a helpful source of information for leading market players, new entrants, investors and stakeholders to strategize for the future and take steps to strengthen their position in the market.

Report coverage and details: